Online inquiry

IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10455MR)

This product GTTS-WQ10455MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10455MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6715MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ8332MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ10634MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ7575MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ8179MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ11649MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ11195MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW